Sanofi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on January 30 2026, recommending a conditional marketing authorization for Rezurock (belumosudil) to treat chronic graft‑versus‑host disease (GVHD) in adults and adolescents weighing at least 40 kg. The decision follows a re‑examination of a prior negative opinion issued in October 2025 and is based on data from the ROCKstar phase 2 study, which reported a 73 % overall response rate within six months of treatment, with 5 % achieving a complete response and 68 % a partial response. The conditional nature of the approval allows early patient access while Sanofi conducts a confirmatory study to further validate efficacy and safety.
The conditional marketing authorization marks a significant regulatory milestone for Sanofi, positioning Rezurock as the first‑in‑class selective ROCK2 inhibitor to receive EU approval for a serious post‑transplant complication. By addressing an unmet need in patients who have exhausted at least two prior lines of systemic therapy, the drug expands Sanofi’s high‑margin biologics portfolio and is expected to generate specialty‑care revenue in a market that values innovative, life‑saving therapies.
Sanofi’s Q4 2025 earnings, released on January 29 2026, showed earnings per share of €1.53 versus analyst estimates of €0.84—a beat of €0.69 or 82 %. The company’s revenue of €11.3 billion fell short of the €13.41 billion consensus, largely because vaccine sales declined 2.5 % to €2.0 billion while Dupixent sales grew 32.2 % to €4.2 billion and new pharma launches rose 49.4 % to €1.1 billion. The earnings beat was driven by strong gross profit of €9.9 billion and disciplined cost management, which offset the revenue miss and allowed Sanofi to maintain profitability despite a €1.2 billion operating loss and a €940 million net loss.
Looking ahead, Sanofi guided for high single‑digit sales growth in 2026 and reaffirmed its €1 billion share‑buyback program. The company’s management highlighted confidence in the continued demand for its immunology products and the strategic importance of Rezurock’s conditional approval, which is expected to accelerate the company’s transformation into an AI‑powered biopharma organization.
Overall, the CHMP decision and the Q4 earnings together underscore Sanofi’s dual focus on expanding its specialty‑care pipeline and delivering solid financial performance. The conditional approval of Rezurock not only brings a new therapy to EU patients but also strengthens Sanofi’s competitive position in the high‑margin biologics market, supporting the company’s long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.